Literature DB >> 12454368

Biochemical and immunological properties of four intravenous Immunoglobulin G preparations.

E L-Rashdy M Redwan1.   

Abstract

Intravenous Immunoglobulin G (IVIG) is one of the most important and widely used human plasma fractions. Although of this there are some precautions should be considered to use this product; e.g. biochemical, biological, immunological, and safety (virus transmission) for each produce patch. The aim of this study was to investigate four commercial IVIG preparations used in Egyptian hospitals. The results show that IVIG from Korean Green Cross Cooperation and Octapharma contained 100% intact IgG, while IVIG-VACSERA and VIGAM-S contained 98-99% intact IgG. IgG subclass distribution corresponded to the distribution in normal human plasma, except for IVIG-VACSERA, where IgG_2 slightly elevated. IVIG-VACSERA and VIAGM-S contained acceptable traces of IgA/IgM, while preparations from both Korean Green Cross Cooperation and Octapharma contained 130/150 and 100/80 microg/ml, respectively. Each preparation had a strong potential to react with respiratory and enteric bacterial LPS and tetanus toxoid antigen. Our results are in general agreement with previous status of worldwide diphtheria immunity status. The immunoreactivity with the other antigen will discuss.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454368

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  5 in total

Review 1.  Intravenous immunoglobulin in immunodeficiency states: state of the art.

Authors:  Elias Toubi; Amos Etzioni
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease.

Authors:  Koichi Sakata; Kenji Hamaoka; Sei-Ichiro Ozawa; Ayumi Niboshi; Takao Yoshihara; Tesuo Nishiki; Yumi Nakagawa; Kikuko Kazuta; Yoshiko Morimoto; Yasutaka Kamiya; Toru Yamamoto; Yoshihiro Horii; Sachiko Kido
Journal:  Eur J Pediatr       Date:  2007-06       Impact factor: 3.183

3.  Anti-infectivity of camel polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma.

Authors:  Esmail M El-Fakharany; Nawal Abedelbaky; Bakry M Haroun; Lourdes Sánchez; Nezar A Redwan; Elrashdy M Redwan
Journal:  Virol J       Date:  2012-09-16       Impact factor: 4.099

4.  Elevated Concentration of Defensins in Hepatitis C Virus-Infected Patients.

Authors:  Ehab H Mattar; Hussein A Almehdar; Abdullah A AlJaddawi; Isam ElDin M Abu Zeid; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-06-20       Impact factor: 4.818

5.  Simple and efficient protocol for immunoglobulin Y purification from chicken egg yolk.

Authors:  Elrashdy M Redwan; Abdullah A Aljadawi; Vladimir N Uversky
Journal:  Poult Sci       Date:  2020-12-24       Impact factor: 3.352

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.